Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Hepatitis E infection is usually a self-limiting disease. In industrialized countries, sporadic cases of acute hepatitis E virus (HEV) infections have been described; their number seems to be increasing in European countries. We report the first human case of autochthonous acute hepatitis E confirmed in Portugal. Patients with acute non-A-C hepatitis should be tested for HEV in Portugal and hepatitis E infection should be considered in the differential diagnosis of unexplained hepatitis cases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3855/jidc.2078 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Yeast-Derived Glucan Particles: Biocompatibility, Efficacy, and Immunomodulatory Potential as Adjuvants and Delivery Systems.
Pharmaceutics
August 2025
CNC-UC-Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal.
: Glucan particles (GPs), derived from yeast, possess unique biomedical properties. Nevertheless, it is imperative that a comprehensive risk assessment is conducted during pre-clinical development. GPs are primarily constituted of a naturally occurring polymer known as β-glucan.
View Article and Find Full Text PDFApproaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries with the Highest Adult HIV Prevalence.
Clin Infect Dis
August 2025
Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA.
Expanded access to dolutegravir as part of a fixed-dose combination with tenofovir disoproxil fumarate and lamivudine (TLD) has revolutionized global HIV treatment, with more than 25 million people prescribed this regimen in 2024. We reviewed national clinical guidelines for management of virologic failure on first-line TLD in the 50 countries with the highest prevalence of HIV among adults; recent guidelines were not available online for four. Among the remaining 46 country guidelines, we identified four distinct approaches: 1) empiric switch to a protease inhibitor (PI)-based regimen without genotypic resistance testing (GRT) (n=28; 61%); 2) GRT to guide antiretroviral therapy selection (n=14; 30%); 3) continuation of TLD without GRT (n=3; 7%); and 4) empiric switch to a PI-based regimen with concurrent GRT (n=1; 2%).
View Article and Find Full Text PDFDrug-related infectious diseases (DRID), such as HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV), contribute to high morbidity and mortality among people who inject drugs (PWID). The European Union Drugs Agency (EUDA) is responsible for monitoring DRID and related behaviours for PWID in Europe. We updated the EUDA DRID technical protocol which covers all steps from planning to data analysis needed for a survey among PWID.
View Article and Find Full Text PDFAbsence of hepatitis E virus RNA in bovines from Portugal.
Vet Res Commun
July 2025
School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal.
Hepatitis E virus (HEV) is widely recognized as an emerging public health issue in developed countries, with most infections linked to foodborne transmission of genotype HEV-3. This zoonotic genotype can infect a diverse range of mammalian species, including bovine, with pigs serving as the primary reservoir. The aim of the present study was to investigate the occurrence, circulation, and the potential of HEV infection among bovines in Portugal.
View Article and Find Full Text PDFOptimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions.
Open Forum Infect Dis
July 2025
SHARE Collaborative, Blizard Institute, Queen Mary University of London, London, UK.
Cabotegravir plus rilpivirine long-acting (CAB + RPV-LA) injectable therapy marks a major milestone in HIV care, offering an efficacious, well-tolerated alternative to daily oral antiretroviral treatment. This article reviews data from pivotal trials and observational studies of CAB + RPV-LA, addressing emerging questions and highlighting key research priorities. We examine factors influencing virological outcomes, including issues related to HIV subtype, archived drug resistance, body mass index, and pharmacokinetics, and discuss challenges related to hepatitis B virus immunity and infection, pregnancy, and adherence.
View Article and Find Full Text PDF